ABSTRACT:
Worldwide, each year over 30,000 patients undergo an allogeneic hematopoietic stem cell transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency, metabolic disease, or a life-threatening bone marrow failure syndrome. Graft-versus-host disease (GVHD) is a complex and debilitating condition that affects a significant proportion of patients who undergo hematopoietic stem cell transplantation. Digital twin technology has emerged as a revolutionary approach in various fields, including healthcare. Digital twins are virtual replicas of physical systems, that simulate their behavior and predict their responses to various scenarios. In the context of graft-versus-host disease (GVHD),digital twins offer a promising tool for personalized medicine. This enables to simulate different treatment scenarios, optimize therapies, and predict treatment outcomes more accurately. By creating virtual models of individual patients' physiology and disease progression, clinicians can simulate various treatment scenarios and predict outcomes. This enables informed decision-making, reduced uncertainty, and improved patient outcomes.
Cite this article:
Jyothsna Moganti*, Nookaratnam P, Venkataramana G, Bhavani Boddeda. Digital Twin Technology in Graft Vs Host Disease . IJRPAS, March 2025; 4 (3): 79-88.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2025.4311
1. Socié G, Ritz J. Current issues in chronic
graft-versus-host disease. Blood. 2014 Jul 17;124(3):374-84.
2.
Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and
supportive care of chronic graft-versus-host disease: national institutes of health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working
Group Report. Biology of Blood and Marrow Transplantation. 2006;12(4):375-396.
3.
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes
of Health Consensus Development Project on Criteria for Clinical Trials in
Chronic Graft-versusHost Disease: I. Diagnosis and Staging Working Group
Report. Biology of Blood and Marrow Transplantation. 2005;11(12):945-956.
4. Majhail NS, Farnia SH,
Carpenter PA, et al. Indications for autologous and allogeneic
hematopoietic cell transplantation: Guidelines from the American Society for
Blood and Marrow Transplantation. Biol Blood Marrow Transplant.
2015;21(11):1863-9. doi:10.1016/j.bbmt.2015.07.032.
5. Akahoshi Y, Spyrou N,
Hogan WJ, Ayuk F, DeFilipp Z, Weber D, et al. Incidence, clinical
presentation, risk factors, outcomes, and biomarkers in de novo late acute
GVHD. Blood Adv. 2023 Aug 22;7(16):4479-4491. doi: 10.1182/bloodadvances.2023009885.
6.
De Bruyne B. and Sarma J.,
“ Fractional flow reserve: A review,” Heart 94(7), 949–959 (2008). 10.1136/hrt.2007.122838.
7.
De Benedictis A, Mazzocca
N, Somma Aet al. et al. Digital twins in healthcare: an architectural
proposal and its application in a social distancing case study. IEEE J Biomed Health Inform 2022.
Epub ahead of print. doi: 10.1109/JBHI.2022.3205506.
8.
Digital twins in clinical research: Revolutionizing study design
[Internet]. LinkedIn; [cited 2025 Mar 6]. Available from:
https://www.linkedin.com/pulse/digital-twins-clinical-research-revolutionizing-study-design-xq7ze?utm_source=share&utm_medium=member_android&utm_campaign=share_via.